Orgenesis Inc. (OTCPK: ORGS)
Health Care · Biotechnology · US
$0.10
-71.43% today · 0.0% 1Y
Orgenesis Inc. (OTCPK: ORGS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $979.95K and employs 77 people.
Over the last twelve months the share price has gained 0.0%, trading between 0.00 and 1.00.
Tweenvest scores Orgenesis Inc. across four factors: quality 7/100, value 40/100, growth 100/100. Its strongest factor is growth.
ORGS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $979.95K
- Revenue (TTM)
- $1.03M
- P/E
- —
- EPS
- -11.44
- Dividend yield
- —
- Beta (5Y)
- 3.35
- 52-week high
- $1.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 9.80M
- Employees
- 77
- Next earnings
- —
About Orgenesis Inc.
Orgenesis Inc. is a global biotechnology firm dedicated to the field of cell and gene therapies. The company has engineered an innovative Point of Care (POCare) platform. This system incorporates a portfolio of licensed POCare therapeutics, which are manufactured and prepared using automated, self-contained POCare technology within a cooperative network. Orgenesis primarily concentrates on autologous therapies, developing customized processes and systems for each treatment. These utilize a closed, automated processing methodology, validated for safe and compliant production directly at the patient's location, facilitating immediate therapeutic application. Established in 2008 as Business Outsourcing Service, Inc., the company adopted the name Orgenesis Inc. in August 2011 and is headquartered in Germantown, Maryland.
- ISIN
- US68619K3032
- Founded
- 2008
- Listed since
- Mar 13, 2012
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.